Movin'on Up: Finding the Right Lab Space for Your Growing Company

Event Information

Share this event

Date and Time



Genesis at Campus Point

4242 Campus Point Court

San Diego, CA 92121

View Map

Event description


Whether you are a PI coming out of a university, running experiments out of your garage or working at a shared lab space, the time eventually will come to leave the nest and lease your own space. But where to begin to consider the right location, providing room for future expansion, and knowing the terms of a typical lease agreement? Join us to hear from David Marino, Executive Vice President of Hughes Marino, on how to compare your options and make a smart leasing decision. The session includes a panel discussion with cancer-selective gene therapy pioneers from Tocagen. Tocagen has experienced growth pains, lived to tell about it and has graciously offered to show the startup community their new space located on-site - Genesis at Camous Point.


11:30 - 12:00p - Lunch & networking

12:00 - 12:20p - Introduction & market overview by David Marino, Executive Vice President and Shane Poppen, Senior Vice President of Hughes Marino

12:20 - 1:00p - Panel discussion with Marty Duvall (CEO) and Mark Foletta (CFO) of Tocagen on how they have grown from incubator space to a home of their own at Genesis at Campus Point

1:00 – 1:30p – Optional Tour of Tocagen’s Amazing Space – Limited to three groups of 15 for 10 minute increments (sign-up sheet will be provided)


David Marino, Executive Vice President of Hughes Marino

David Marino is executive vice president of Hughes Marino, and co-leads the Hughes Marino Life Sciences Tenant Services team. David specializes in high-value, time-critical and complex transactions for biotech, medical device, instrumentation and healthcare companies. He is an expert in the strategic planning, market assessment, financial analysis, business terms structuring and negotiations aspects of commercial real estate. David has an in-depth command of the entire facility lease, purchase and disposition process.

After finishing his MBA at USC, David began his commercial real estate career with Trammell Crow Company in 1989, during which David leased the properties for all of Hybritech’s R&D and manufacturing space. In 1990, David was the landlord side broker who completed the first lease with Dura Pharmaceuticals. In that same year he completed his first career tenant representation project for Baxter Healthcare for 25,000 square feet. It was that experience that sparked David’s passion for tenant representation and helped him realize the value that his MBA training and landlord experience would bring to tenants. David has been exclusively representing tenants since 1991, completing over 20,000,000 square feet, comprised of over 1,000 transactions.

Selected public company clients include: Alphatec Spine, 75,000 and 150,000 SF; La Jolla Pharmaceutical Company, 83,000 SF; Nuvasive, 252,000 SF; Pfenex, 45,000 SF; Senomyx, 65,000 SF; Sequenom, 82,000 SF; Tandem Diabetes, 49,000 and 75,000 SF; Tocagen, 39,000 SF; Tracon, 4,000, 7,000 and 9,000 SF; Vical, 68,000 SF; Vital Therapies, 5,000 and 15,000 SF; and Volcano Corporation, where David did all of their work in North America for over a dozen leases, ranging from 3,000 to 92,000 SF.

Selected venture-backed and private equity funded clients include: Accriva, 130,000 SF; Agena, 55,000 SF; BioLegend, 66,000 and 136,000 SF; BioSurplus, 12,000 SF; Host Healthcare, 8,000 and 12,000 SF; Inova Diagnostics, 45,000 and 76,000 SF; Medimpact, 26,000 and 45,000

SF; Optovue, 60,000 SF; Samumed, 25,000 SF; Sekisui Diagnostics, 45,000 SF; Vyaire Medical, 185,000 SF; Xifin, 58,000 SF; and Zest Anchors, 45,000 SF.

Selected nonprofit research clients include: The Salk Institute for 10,000 SF; and The Scripps Research Institute, 60,000 SF and 112,000 SF.


• University of Southern California, MBA with emphasis in real estate & finance

• University of California, Riverside, B.S. in economics

Professional Activities

• University of San Diego Graduate School of Real Estate

– Guest Lecturer

• University of Southern California Graduate School of Real Estate

– Guest Lecturer

• University of Washington Graduate School of Business and Undergraduate Business School

– Guest Lecturer

• California Department of Real Estate Licensed Broker

– Broker License #01059021

Honors and Awards

• The Irvine Company’s “Broker of the Year” every year since 2005

Shane Poppen, Senior Vice President of Hughes Marino

Shane Poppen is a senior vice president at Hughes Marino, an award-winning commercial real estate firm that exclusively represents tenants and buyers, never landlords. With over 10 years and 4,000,000 square feet of transaction experience, Shane combines his strong market knowledge and the firm’s tenant-focused discipline to create leverage and opportunities, aligning his client’s real estate goals with their business plan to deliver the most strategically correct, cost-effective and risk-reducing project outcomes possible.

His experience includes site selection, strategic planning and needs assessment, financial analysis, negotiation and transaction structuring for lease renewals, relocations, renegotiations and building purchases.

Shane Poppen graduated with provost honors and a B.A. in economics from the University of California, San Diego. He was a four-year letter winner and captain of UCSD’s basketball team. Shane is an active volunteer in the community, serving on the Board of Directors for the McAlister Institute which provides drug treatment and services to adults and teens throughout San Diego County, Board committee member for Feeding America San Diego, as camp director for Bill Walton’s inaugural Inter-Tribal Sports basketball camp supporting San Diego’s Native American youth, and as youth basketball coach for the San Diego YMCA.

Shane currently resides in Encinitas and enjoys spending free time with his wife, Becky, daughter, Anabelle and son, Owen.

Marty Duvall, CEO of Tocagen

Marty J. Duvall has served as Tocagen’s chief executive officer and as a member of our board of directors since November 2016. He holds over 30 years of oncology drug development and commercialization experience, including building successful oncology teams in both large pharma organizations and biotech companies. Prior to joining Tocagen, Mr. Duvall served as executive vice president, chief commercial officer of ARIAD Pharmaceuticals, Inc., a publicly held biotechnology company, from September 2011 to June 2016, where he led the company’s growth and transformation into a fully integrated, global biotechnology company. From December 2010 to September 2011, he served as senior vice president and general manager for the oncology franchise at Merck & Co., Inc., a publicly held healthcare company. Prior to that, he served in similar capacities at Abraxis Bioscience, Inc., a publicly held biotechnology company now acquired by Celgene; MGI Pharma, Inc., a publicly held biopharmaceutical company now acquired by Eisai Co., Ltd.; and in positions of increasing responsibility at Sanofi US, a publicly held biotechnology company, and its predecessor companies. Mr. Duvall received a bachelor’s degree in chemistry from Muhlenberg College, master’s degree in chemistry from Johns Hopkins University and master’s degree in business administration from the University of Kansas.

Mark Foletta, Executive Vice President and CFO of Tocagen

Mark Foletta has served as Tocagen’s executive vice president and chief financial officer since February 2017. He holds more than 30 years of experience in finance and accounting. Prior to joining Tocagen, Mr. Foletta served as the interim chief financial officer of Biocept, Inc., a publicly held diagnostics company, from August 2015 to July 2016. Mr. Foletta served as senior vice president, finance and chief financial officer of Amylin Pharmaceuticals, Inc., or Amylin, a publicly held biopharmaceutical company, from March 2006 until October 2012 when the company was acquired by Bristol-Myers Squibb, and as vice president, finance and chief financial officer of Amylin from March 2000 until March 2006. Mr. Foletta serves as a member of the board of directors, chairman of the audit committee and member of the nominating and governance committee of Regulus Therapeutics, Inc., a publicly held biopharmaceutical company, as lead director of the board of directors and chairman of the audit committee of DexCom, Inc., a publicly held medical device company and as a member of the board of directors and chairman of the audit committee of Amn Healthcare Services, Inc., a publicly held healthcare workforce and staffing company, and Viacyte, Inc., a privately held biotechnology company. He is a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.


Share with friends

Date and Time


Genesis at Campus Point

4242 Campus Point Court

San Diego, CA 92121

View Map

Save This Event

Event Saved